Takeda Pharmaceutical Company Limited (NYSE:TAK - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $15.22 and last traded at $15.20, with a volume of 561724 shares trading hands. The stock had previously closed at $15.01.
Takeda Pharmaceutical Trading Up 0.6 %
The stock has a market capitalization of $48.51 billion, a PE ratio of 38.14, a price-to-earnings-growth ratio of 0.24 and a beta of 0.46. The firm has a 50-day moving average price of $13.91 and a 200-day moving average price of $13.92. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63.
Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its quarterly earnings data on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. As a group, equities analysts forecast that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in the stock. First Trust Advisors LP boosted its position in shares of Takeda Pharmaceutical by 2.0% during the 4th quarter. First Trust Advisors LP now owns 3,240,932 shares of the company's stock valued at $42,910,000 after acquiring an additional 62,718 shares during the last quarter. FMR LLC increased its stake in Takeda Pharmaceutical by 10.9% in the 3rd quarter. FMR LLC now owns 2,908,918 shares of the company's stock worth $41,365,000 after purchasing an additional 286,052 shares during the period. Van ECK Associates Corp increased its stake in Takeda Pharmaceutical by 1.6% in the 4th quarter. Van ECK Associates Corp now owns 2,210,428 shares of the company's stock worth $29,266,000 after purchasing an additional 35,192 shares during the period. Northern Trust Corp increased its stake in Takeda Pharmaceutical by 14.6% in the 4th quarter. Northern Trust Corp now owns 1,873,588 shares of the company's stock worth $24,806,000 after purchasing an additional 238,161 shares during the period. Finally, Managed Asset Portfolios LLC increased its stake in shares of Takeda Pharmaceutical by 0.3% during the third quarter. Managed Asset Portfolios LLC now owns 1,617,541 shares of the company's stock valued at $23,001,000 after buying an additional 4,069 shares during the period. Hedge funds and other institutional investors own 9.17% of the company's stock.
About Takeda Pharmaceutical
(
Get Free Report)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
Featured Stories
Before you consider Takeda Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Takeda Pharmaceutical wasn't on the list.
While Takeda Pharmaceutical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
